Aesica Pharmaceuticals, a contract development and manufacturing organization, has doubled its development capacity at it facility in Queenborough, UK. With the addition of the new capabilities, Aesica can now develop and manufacture a customer product from early formulation development through clinical manufacture and into commercialization. 

The company's high potent and controlled drugs service offering has been expanded at Queenborough as a result of the new center. The company previously only provided commercials-scale manufacturing capabilities for these drug classifications, but it now offers full formulation and development capabilities in these specialist fields. The site handles high potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both Schedules 2 to 4. Moreover, the facility is experienced in handling drugs that are both highly potent and at the same time controlled.

Source: Aesica Pharmaceuticals